50 Studies Every Neurologist Should Know

50 Studies Every Neurologist Should Know presents key studies that shape the current clinical practice of neurology. All neurologic subspecialties are covered, with a special emphasis on neurocritical care and vascular neurology. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This is the first book of its kind to present a collection of the most influential clinical trials in neurology that are detailed enough to be used on rounds, but still easily digestible. It is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice.

Table of Contents

Section I: Behavioral Neurology
1. Cholinesterase Inhibitors for Alzheimer's Disease
2. Memantine for Alzheimer's Disease
Section II: Epilepsy
3. Lorazepam for Generalized Status Epilepticus
4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial
5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial
Section III: Headache
6. Sumatriptan for Acute Migraine
Section IV: Neuroinfectious Disease
7. Steroids for Bell's Palsy
8. Steroids for Acute Bacterial Meningitis
Section V: Movement Disorders
9. Levadopa for Parkinson's Disease
10. Deep-Brain Stimulation for Parkinson's Disease
Section VI: Multiple Sclerosis
11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis
12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial
13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial
14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial
15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial
16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial
Section VII: Neurocritical Care
18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial
19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial
20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial
21. Nimodipine for Subarachnoid Hemorrhage
Section VIII: Neuromuscular Disease
22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome
23. IVIG vs. Plasma Exchange for Myasthenia Gravis
24. Riluzole for Amyotrophic Lateral Sclerosis
Section IX: Neuro-Oncology
25. Radiotherapy Plus Temozolomide for Glioblastoma
26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma
Section X: Neuro-Ophthalmology
27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial
Section XI: Neuro-Otology
28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo
Section XII: Sleep
29. Modafinil for Narcolepsy
30. Continuous Dopamine Agonist for Restless Legs Syndrome
Section XIII: Spine Disorders
31. Early Surgery for Sciatica
32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial
33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial
Section XIV: Vascular Neurology
34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial
35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial
36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial
37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial
38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial
39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial
40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I
41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II
42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial
43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial
44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial
45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial
46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial
47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial
48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial
49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial
50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial

Edited by David Y. Hwang, Assistant Professor of Neurology, Yale University School of Medicine, Edited by David M. Greer, Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology, Yale University School of Medicine, and Series edited by Michael E. Hochman, Medical Director; Robert Wood Johnson Foundation Clinical Scholar, Innovation, AltaMed Health Services; Department of Internal Medicine, University of California, Los Angeles

David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut. David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.